跳至主要内容
临床试验/NCT07724938
NCT07724938招募中不适用

Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse

Brigham and Women's Hospital2 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2026年9月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
72
试验地点
2
主要终点
Percent reduction in apnea-hypopnea index (AHI)

研究概览

简要总结

The goal of this clinical trial is to learn whether removing the tonsils at the time of hypoglossal nerve stimulation improves treatment of obstructive sleep apnea in adults whose airway collapses from the side of the upper airway during sleep. The main questions it aims to answer are:

  1. Does hypoglossal nerve stimulation combined with tonsillectomy reduce the severity of obstructive sleep apnea more than hypoglossal nerve stimulation alone?
  2. Does tonsillectomy improve how effectively hypoglossal nerve stimulation opens and stabilizes the upper airway?

Researchers will compare participants who receive hypoglossal nerve stimulation with tonsillectomy to participants who receive hypoglossal nerve stimulation alone.

Participants will:

  • Complete sleep studies, questionnaires, and other assessments before and after treatment
  • Be randomly assigned to receive hypoglossal nerve stimulation either with or without tonsillectomy
  • Return for follow-up visits and sleep testing to evaluate treatment effectiveness
  • In a subset of participants, complete additional overnight testing to measure how treatment changes upper-airway collapsibility

详细描述

Obstructive sleep apnea (OSA) is commonly treated with hypoglossal nerve stimulation (HGNS), but treatment efficacy is substantially reduced in patients with complete oropharyngeal lateral wall (OPLW) collapse. HGNS primarily enlarges the airway by protruding the tongue and is therefore most effective in patients with anteroposterior patterns of airway collapse. Tonsillectomy reduces tissue contributing to lateral pharyngeal narrowing and may complement the mechanism of HGNS by addressing residual lateral wall obstruction. Preliminary clinical data suggest that combining tonsillectomy with HGNS substantially improves treatment response compared with HGNS alone in patients with OPLW collapse, but this strategy has not been evaluated in a randomized clinical trial.

This prospective, randomized controlled trial will enroll 72 adults with moderate-to-severe OSA, complete OPLW collapse identified on drug-induced sleep endoscopy, and candidacy for both HGNS implantation and tonsillectomy. Participants will be randomized 1:1 to receive either concurrent HGNS implantation plus tonsillectomy or HGNS implantation alone. All participants will undergo standard postoperative device activation and titration. The primary efficacy endpoint will be assessed after approximately one month of optimized HGNS therapy using sleep studies and patient-reported outcomes. Participants in the HGNS-alone group with persistent OSA may subsequently undergo delayed tonsillectomy as part of standard clinical care, permitting additional within-subject mechanistic comparisons.

The primary objective is to determine whether concurrent tonsillectomy improves the effectiveness of HGNS in reducing OSA severity compared with HGNS alone. Secondary objectives are to determine whether tonsillectomy enhances HGNS-induced improvements in upper-airway collapsibility and to evaluate whether tonsillectomy modifies the physiological effects of HGNS beyond the effects of either treatment alone. In an optional mechanistic substudy, approximately 30 participants will undergo detailed physiological sleep studies to measure pharyngeal collapsibility using gold-standard techniques, providing insight into the mechanisms underlying any observed improvement in clinical outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Because treatment assignment determines the surgical procedure and subsequent study schedule, participants, treating surgeons, and study personnel responsible for clinical care, safety monitoring, scheduling, and study operations will not be blinded to treatment assignment. Outcomes assessors (e.g., principal investigator, postdoc fellow) may become aware of treatment assignment through protocol oversight or participant safety monitoring but will not participate in blinded primary outcome scoring. To minimize assessment bias, sleep studies used for the primary endpoint will be prepared by an unblinded study team member not involved in outcome assessment. Files will be assigned blinded assessment identifiers and stripped of treatment assignment and other information that could reveal allocation. Primary endpoint scoring will be performed by personnel blinded to treatment assignment, and the primary analysis will be conducted using coded treatment groups until the analysis is finalized.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Diagnosis of obstructive sleep apnea with apnea-hypopnea index (AHI) ≥ 15 events/hour
  • Complete oropharyngeal lateral wall (OPLW) collapse identified on DISE
  • Candidate for HGNS implantation based on standard clinical criteria
  • Presence of small (1-2+) tonsils and eligibility for tonsillectomy
  • Untreated OSA at the time of enrollment
  • Willing and able to provide written informed consent

排除标准

  • Absence of tonsils
  • Presence of large tonsils (3-4+; not eligible for HGNS)
  • Predominant central or mixed sleep apnea (>25% central or mixed events)
  • Any unstable or serious medical condition that, in the opinion of the investigator, would increase risk or interfere with study participation
  • Ineligibility for HGNS implantation based on standard clinical or surgical criteria
  • Inability to comply with study procedures or follow-up assessments

研究组 & 干预措施

HGNS plus tonsillectomy

Experimental

HGNS plus concomitant tonsillectomy

干预措施: Tonsillectomy (Procedure)

HGNS plus tonsillectomy

Experimental

HGNS plus concomitant tonsillectomy

干预措施: HGNS (Device)

HGNS

Active Comparator

HGNS alone (without concomitant tonsillectomy)

干预措施: HGNS (Device)

结局指标

主要结局

Percent reduction in apnea-hypopnea index (AHI)

时间窗: 1 month of optimized therapy.

Percent reduction in the apnea-hypopnea index (AHI), measured by overnight polysomnography, from baseline to the primary follow-up sleep study. Higher values indicate greater improvement in obstructive sleep apnea.

次要结局

  • Absolute change in apnea-hypopnea index(1 month of optimized therapy.)
  • Treatment success(1 month of optimized therapy)
  • Change in Sleep Apnea Hypoxic Burden from Baseline(1 month of optimized therapy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel Vena, PhD

Assistant Professor of Medicine, Harvard Medical School; Associate Scientist, Brigham and Women's Hospital

Brigham and Women's Hospital

研究点 (2)

Loading locations...

相似试验